Yahoo · Aug 12, 2026
Recursion (RXRX) Q2 2026 Earnings Call Transcript
AI-native drug discovery advances neuroscience target with Roche while cutting cash guidance.
RX
NASDAQ · RXRX
Recursion Pharmaceuticals, Inc. Class A Common Stock
Healthcare · Biotechnology
$3.63
Up+$0.19 (+5.52%)
Updated Sep 5, 2026, 4:20 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.83B
- P/E ratio
- -2.94
- Dividend yield
- 0.00%
- 52-week range
- $2.77 – $7.18
- Volume
- 29.04M
- Avg. volume
- 43.4M
Price performance
RXRX price history
1M range · 21 trading sessions · Daily adjusted prices
RXRX closed at $3.63 after 21 trading sessions, up 12.73% for the selected period.
- Last close
- $3.63
- Period change
- +12.73%
- Period low
- $3.09
- Period high
- $3.63
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $3.415 | $3.70 | $3.41 | $3.63 | 29.04M |
| Sep 3, 2026 | $3.435 | $3.45 | $3.2901 | $3.44 | 13.75M |
| Sep 2, 2026 | $3.34 | $3.4891 | $3.285 | $3.38 | 14.05M |
| Sep 1, 2026 | $3.34 | $3.38 | $3.2801 | $3.33 | 10M |
| Aug 31, 2026 | $3.305 | $3.41 | $3.25 | $3.40 | 13.91M |
| Aug 28, 2026 | $3.40 | $3.45 | $3.31 | $3.34 | 10.56M |
| Aug 27, 2026 | $3.515 | $3.5499 | $3.42 | $3.44 | 10.99M |
| Aug 26, 2026 | $3.51 | $3.55 | $3.43 | $3.49 | 12.98M |
| Aug 25, 2026 | $3.27 | $3.59 | $3.26 | $3.56 | 22.52M |
| Aug 24, 2026 | $3.42 | $3.44 | $3.215 | $3.25 | 15.16M |
| Aug 21, 2026 | $3.39 | $3.6299 | $3.37 | $3.50 | 22.9M |
| Aug 20, 2026 | $3.40 | $3.46 | $3.27 | $3.34 | 21.45M |
| Aug 19, 2026 | $3.275 | $3.50 | $3.19 | $3.50 | 30.37M |
| Aug 18, 2026 | $3.03 | $3.10 | $2.92 | $3.09 | 16.35M |
| Aug 17, 2026 | $3.12 | $3.16 | $3.08 | $3.11 | 10.62M |
| Aug 14, 2026 | $3.30 | $3.305 | $3.14 | $3.16 | 10.55M |
| Aug 13, 2026 | $3.31 | $3.35 | $3.27 | $3.31 | 10.7M |
| Aug 12, 2026 | $3.37 | $3.38 | $3.26 | $3.29 | 10.31M |
| Aug 11, 2026 | $3.32 | $3.42 | $3.27 | $3.35 | 11.01M |
| Aug 10, 2026 | $3.20 | $3.36 | $3.19 | $3.29 | 14.03M |
| Aug 7, 2026 | $3.2541 | $3.265 | $3.18 | $3.22 | 9.36M |
Latest RXRX news
The latest Smart Investors Daily articles mentioning RXRX.
Stock researchCompany · Overview
RXRX research
Overview
Company profile and research snapshot.
Company profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Morgan Stanley | Equal-Weight | — |
| May 7, 2026 | Needham | Buy | — |
| Apr 30, 2026 | JP Morgan | Overweight | — |
| Feb 26, 2026 | Needham | Buy | — |
| Feb 26, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 11, 2026
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Bank of America SMID Cap Virtual Conference August 11, 2026 10:00 AM EDTCompany ParticipantsBen Taylor - CFO &...
SeekingAlpha · Aug 9, 2026
Recursion Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-09. The following slide deck was published by Recursion Pharmaceuticals, Inc.
Yahoo · Aug 5, 2026
Recursion Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Recursion Pharmaceuticals, Inc.'s Q2 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
